Is that what Sustainable Earning stands for?: KemPharm Inc. (KMPH)

A share price of KemPharm Inc. [KMPH] is currently trading at $4.71, down -1.67%. An important factor to consider is whether the stock is rising or falling in short-term value. The KMPH shares have gain 7.29% over the last week, with a monthly amount drifted -16.49%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


On 18, November 2022, KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH). In a post published today on Yahoo Finance, Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022.

From an analyst’s perspective:

KemPharm Inc. [NASDAQ: KMPH] stock has seen the most recent analyst activity on November 17, 2022, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $20. Previously, Canaccord Genuity started tracking the stock with Buy rating on September 15, 2022, and set its price target to $20. On January 31, 2022, upgrade upgraded it’s rating to Buy and revised its price target to $11 on the stock. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $12 on March 04, 2021. ROTH Capital initiated its recommendation with a Buy and recommended $28 as its price target on January 25, 2021.

KemPharm Inc. experienced fluctuations in its stock price throughout the past year between $4.00 and $9.43. Currently, Wall Street analysts expect the stock to reach $19.25 within the next 12 months. KemPharm Inc. [NASDAQ: KMPH] shares were valued at $4.71 at the most recent close of the market. An investor can expect a potential return of 308.7% based on the average KMPH price forecast.

Analyzing the KMPH fundamentals

During the last quarter, KemPharm Inc. [NASDAQ:KMPH] saw sales of 2.87 billion, an improvement of 45.00%. Gross Margin for this corporation currently stands at +91.92% with Operating Margin at +26.98%, Pretax Margin comes in at -29.74%, and Net Margin reading is -29.86%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.65 points at the first support level, and at 4.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.81, and for the 2nd resistance point, it is at 4.92.

KemPharm Inc. [KMPH] reported earnings per share of -$0.7 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.12/share, meaning a difference of -$0.58 and a surprise factor of -483.30%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.05 per share as compared to estimates of -$0.05 per share, a difference of $0 representing a surprise of 0.00%.

Ratios To Look Out For

A current ratio of 10.10 is a noteworthy aspect of KemPharm Inc. [NASDAQ:KMPH]. On the other hand, the Quick Ratio is 27.20, and the Cash Ratio is 26.56. Considering the valuation of this stock, the price to sales ratio is 9.05, the price to book ratio is 2.40.

Transactions by insiders

The next item on our agenda is insider trading, which has seen 2 insider purchases totaling 1,000 shares and 0 insider sales totaling 0 shares over the past 3 months. Recent insider trading involved Clifton R. LaDuane, CFO, Secretary & Treasurer, that happened on Sep 30 when 1000.0 shares were purchased. President & CEO, Mickle Travis C completed a deal on May 25 to buy 10000.0 shares. Meanwhile, President & CEO Mickle Travis C bought 3000.0 shares on May 25.